Department of Onco-hematology, Cell and Gene Therapy, Bambino Gesù Children's Hospital-IRCCS, 00146 Rome, Italy.
Department of Clinical Medicine and Surgery, Federico II University of Naples, 81100 Naples, Italy.
Cells. 2020 Dec 24;10(1):14. doi: 10.3390/cells10010014.
The adoptive transfer of the chimeric antigen receptor (CAR) expressing T-cells has produced unprecedented successful results in the treatment of B-cell malignancies. However, the use of this technology in other malignancies remains less effective. In the setting of solid neoplasms, CAR T-cell metabolic fitness needs to be optimal to reach the tumor and execute their cytolytic function in an environment often hostile. It is now well established that both tumor and T cell metabolisms play critical roles in controlling the immune response by conditioning the tumor microenvironment and the fate and activity of the T cells. In this review, after a brief description of the tumoral and T cell metabolic reprogramming, we summarize the latest advances and new strategies that have been developed to improve the metabolic fitness and efficacy of CAR T-cell products.
嵌合抗原受体 (CAR) 表达 T 细胞的过继转移在治疗 B 细胞恶性肿瘤方面取得了前所未有的成功。然而，该技术在其他恶性肿瘤中的应用效果仍不理想。在实体肿瘤中，CAR T 细胞的代谢适应性需要最佳，以到达肿瘤并在通常敌对的环境中发挥其细胞溶解功能。现在已经明确，肿瘤和 T 细胞代谢都通过调节肿瘤微环境以及 T 细胞的命运和活性，在控制免疫反应方面发挥着关键作用。在简要描述肿瘤和 T 细胞的代谢重编程之后，我们总结了为提高 CAR T 细胞产品的代谢适应性和疗效而开发的最新进展和新策略。
